Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AdaptHealth Corp (AHCO) vs ResMed Inc. (RMD) Price & Performance

AdaptHealth CorpTrade
ResMed Inc.Trade

Price performance (Past 24H)

Key statistics

AdaptHealth Corp vs ResMed Inc. — how do they compare? AdaptHealth Corp trades at $5.85 (market cap $753.09M), while ResMed Inc. trades at $225.73 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 43.3× AdaptHealth Corp's market cap, and ResMed Inc. pays a 1.17% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.

AHCORMD
Market Cap
$753.09M$32.61B
Sector
HealthHealth
52-Week High
$13.38$293.73
52-Week Low
$5.22$182.82
Enterprise Value
$2.77B$31.97B
Dividend Yield
1.17%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AdaptHealth Corp

AdaptHealth Corp. (AHCO) trades at $5.74, up 9.96% in the last session, yet remains under pressure with a bearish technical signal and recent earnings misses. The company reported a Q2 2026 net loss of $228 million with a -6.82% margin, while selling its diabetes unit to focus on sleep and respiratory care. Valuation ratios show a low P/S of 0.23 and P/B of 0.55, but negative profitability metrics highlight operational challenges.

The outlook is mixed: analyst consensus is bullish with a $11 price target, but risks include ongoing losses, fraud investigations, and cost overruns in fixed-price contracts. Upside depends on successful business restructuring and margin improvement, while downside risks from legal and execution issues persist.

ResMed Inc.

ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.

The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AdaptHealth Corp

AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.

Read more on AHCO

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD